BLFS News & Events

Sees 2026 gross margin in the mid-60% range and continued expansion of adjusted EBITDA margin.

Reports Q4 revenue $24.8M, consensus $24.01M. "2025 was a transformative year for BioLife. We delivered 29% revenue growth, led by sustained strength in our biopreservation media franchise and completed a strategic divestiture that firmly established BioLife as a focused, pure-play cell processing company centered on high-value, recurring revenue. With a streamlined cost structure and a scaled core business, we are now realizing the operating leverage inherent in our model." said Roderick de Greef, CEO. "Looking to 2026, we expect growth across our portfolio, operating margin expansion, continued improvement in adjusted EBITDA, and full year GAAP profitability. Continued growth of the CGT end market - including new, unique therapy approvals, geographic expansions, a shift to earlier lines of treatment and additional indications for approved therapies - will further embed our gold-standard tools into more commercial therapies that drive demand. An improving biotech funding environment, strategic investment by large pharma, and ongoing clinical progress underscore this market's long-term attractiveness and provides a meaningful opportunity ahead for BioLife".

BioLife Solutions has entered into a multi-year supply agreement with Qkine under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing. The agreement provides BioLife with exclusive worldwide distribution rights to specific Qkine products for the CGT market and non-exclusive rights to Qkine products in the CGT market. In addition, the companies intend to collaborate on a process development and validation program to enable Qkine to package certain of its products using BioLife's proprietary CellSeal Connect vial system, which is designed to be incorporated into closed system and/or automated CGT workflows. Cytokines and growth factors play a vital role in the manufacturing of cell and gene therapies by regulating and stimulating cell growth, activation and performance. According to third-party market research, the current global cytokines market is estimated at $500M annually and is projected to grow at a mid-teens compound annual rate, reaching $1B by 2030, driven by expanding CGT development pipelines.